FLUNISOLIDE

Post-LOE

flunisolide

Roche

ANDANASALSPRAY, METERED

Approved

Jun 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

FLUNISOLIDE (flunisolide) by Roche is clinical pharmacology flunisolide has demonstrated potent glucocorticoid and weak mineralocorticoid activity in classical animal test systems. Approved for the nasal symptoms of seasonal, perennial rhinitis. First approved in 2022.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Flunisolide has demonstrated potent glucocorticoid and weak mineralocorticoid activity in classical animal test systems. As a glucocorticoid, it is several hundred times more potent than the cortisol standard. Clinical studies with flunisolide have shown therapeutic activity…

Worked on FLUNISOLIDE at Roche? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

FLUNISOLIDE

Mechanism of Action

Indications (2)